HMG (human menopausal gonadotropin) side effects and safety context

HMG's adverse effects are the cost of its mechanism. The drug's purpose is to recruit several ovarian follicles at once instead of the single dominant follicle a natural cycle produces, and nearly every risk on its label is a consequence of ovaries doing more than they normally would — enlarging, leaking fluid into body cavities, twisting on their pedicle, or releasing multiple eggs. The Menopur prescribing information organizes these into nine numbered warnings (Menopur label, DailyMed), which is an unusually long list and worth reading in full rather than summarized as "OHSS risk."

The label's most common adverse reactions in ART cycles, at a frequency of 2% or greater, are:

• Abdominal cramps, abdominal pain, and abdomen enlarged
• Headache
• Injection-site pain, injection-site reaction, and injection-site inflammation
• OHSS

The clustering of three abdominal entries is not incidental — it is the ovarian enlargement the treatment is designed to produce, felt from the outside. The presence of OHSS on the common list, rather than only in the warnings, is the entry most worth noticing.

In label order: abnormal ovarian enlargement; ovarian hyperstimulation syndrome; pulmonary and vascular complications; ovarian torsion; multi-fetal gestation and birth; congenital malformation; ectopic pregnancy; spontaneous abortion; and ovarian neoplasms.

Several of these are underdiscussed relative to OHSS. Ovarian torsion is a surgical emergency in which an enlarged, heavy ovary rotates and cuts off its own blood supply — a mechanical consequence of successful stimulation. Multi-fetal gestation is a risk to both the pregnancy and the pregnant person, not merely an unexpected outcome. And pulmonary and vascular complications are the systemic end of the OHSS spectrum rather than a separate phenomenon.

Menopur is also Pregnancy Category X — the label states it must not be used in pregnant women — and safety and efficacy have not been established in pediatric patients, nor characterized in women with renal or hepatic insufficiency. No drug-drug interaction studies have been conducted in humans.

The label describes severe OHSS in terms of what leaves the circulation and where it goes: hemoconcentration, electrolyte imbalances, ascites, hemoperitoneum, pleural effusion, hydrothorax, acute pulmonary distress, and thromboembolic reactions. Transient liver-function abnormalities suggestive of hepatic dysfunction — with or without morphologic changes on biopsy — have been reported in association with it.

Two features make OHSS harder to manage than a typical dose-related side effect. It occurs after gonadotropin treatment has been discontinued, so stopping the injections is not the end of the risk window; and it can develop rapidly. This is why the label's counselling section makes duration and monitoring a patient-education topic in its own right.

Somewhat, and in a favourable direction. The published profile of highly purified menotropins reports that compared with recombinant FSH, Menopur appeared to be associated with a less pronounced follicular response and a lower risk of ovarian overstimulation — while still matching rFSH on pregnancy rates in IVF/ICSI despite the lower oocyte yield (PMID 30264288).

That is a genuine comparative safety signal, but it shifts a risk rather than removing one: OHSS remains on Menopur's own common-adverse-reaction list, and the choice between preparations is made by a specialist reading an individual patient's ovarian reserve and prior response.

The recurring structure of gonadotropin safety is that the hazards scale with how well the drug works. A strong follicular response is simultaneously the therapeutic goal and the precondition for OHSS, torsion, and multiple pregnancy — which is why fertility protocols are built around serial estradiol measurements and ultrasound follicle counts, and why dose adjustment rules appear on the label alongside the starting dose. The dosing page covers how that adjustment is structured.